Why Was Replimune (REPL) Stock Moving on Aug 9, 2026?

Replimune is a clinical-stage biotechnology company developing oncolytic virus therapies — viruses engineered to infect and destroy cancer cells directly while also triggering the body's immune system to attack the tumor more broadly. That combination mechanism, virus plus immune activation, is what separates the approach from a conventional chemotherapy or a standalone immunotherapy drug.

The company's therapy, now marketed as TUDRIQEV, received FDA accelerated approval in combination with the checkpoint inhibitor nivolumab, for adults with unresectable advanced cutaneous melanoma whose disease progressed on a prior anti-PD-1 antibody-based regimen. The approval is notable beyond Replimune's own pipeline: it marks the first time an oncolytic virus therapy has been approved in combination with a checkpoint inhibitor, a combination class other biotech companies have been pursuing without a prior approved precedent.

Wedbush responded by upgrading Replimune to Outperform from Neutral and raising its target to $19 a share from $12. The stock traded near its 52-week high of $13.90 in the days following the approval, up 14.8% over the prior week, reflecting the market's read that a first-in-class regulatory approval changes the risk profile of the stock from clinical-trial uncertainty to a commercial-launch story.